|
|
 |
|
Viewing report
|
|
|
|
Alkermes, Inc. (ALKS) - Financial and Strategic Analysis Review
GlobalData, July 2010, Pages: 35
Alkermes, Inc., (Alkermes) is a biotechnology company that develops and manufactures extended-release injectable, pulmonary, and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction, and diabetes. The company mainly manufactures Rispedal Consta for schizophrenia, and also develops and manufactures Vivitrol for alcohol dependence. It also has other products under development such as: Exenatide Once Weekly, Vivitrol for opioid, ALKS 29, ALKS 27 and ALKS 33. The company has its operations in the UK and the US. Alkermes is headquartered in Massachusetts, the US.
Alkermes, Inc. Key Recent Developments
May 13, 2010 Alkermes Reports Net Loss Of $40 Million For Fiscal 2010
Apr 23, 2010 Amylin, Eli Lilly Alkermes Reply To FDA Complete Response Letter For Bydureon
Mar 15, 2010 Eli Lilly, Amylin Pharma, Alkermes Receive Complete Response Letter For Bydureon
Feb 04, 2010 Alkermes Reports Total Revenue Of $44.15 Million In Q3 Fiscal 2010
Dec 15, 2009 Amylin, Eli Lilly, Alkermes Report Positive Results From Study Comparing Exenatide To Byetta
This comprehensive SWOT profile of Alkermes, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including,
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note-: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include,
You get detailed information about the company and its operations to identify potential customers and suppliers.
-The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key
competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered
in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and
efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Customers who bought this item also bought
Amylin Pharmaceuticals, Inc.: PharmaVitae Report
Alkermes, Inc. - Product Pipeline Review - Q4 2010
Alkermes, Inc. - Product Pipeline Review - Q4 2010
Amylin Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011
Amylin Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010
Amylin Pharmaceuticals, Inc. (AMLN) - Financial and Strategic SWOT Analysis Review
Eli Lilly & Co.: PharmaVitae Profile
Amylin Pharmaceuticals, Inc.: SWOT Analysis & Company Profile
Alkermes, Inc. - Product Pipeline Review - H2 2011
Amylin Pharmaceuticals, Inc. (AMLN) - Product Pipeline Analysis
|
|
|
|
